drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00261 | DB00850 | 702 | 1,630 | [
"DDInter93",
"DDInter1432"
] | Anagrelide | Perphenazine | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Major | 2 | [
[
[
702,
25,
1630
]
],
[
[
702,
25,
252
],
[
252,
40,
1630
]
],
[
[
702,
24,
673
],
[
673,
40,
1630
]
],
[
[
702,
6,
7950
],
[
7950,
... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Perphenazine"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{... | Anagrelide may lead to a major life threatening interaction when taken with Hydroxyzine and Hydroxyzine (Compound) resembles Perphenazine (Compound)
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole and Aripiprazole (Compound) resembles Perphenazine (Compound)
Anagr... |
DB05773 | DB09068 | 1,047 | 1,427 | [
"DDInter1848",
"DDInter1948"
] | Trastuzumab emtansine | Vortioxetine | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin r... | Moderate | 1 | [
[
[
1047,
24,
1427
]
],
[
[
1047,
25,
256
],
[
256,
24,
1427
]
],
[
[
1047,
64,
477
],
[
477,
24,
1427
]
],
[
[
1047,
63,
1061
],
[
1061,
... | [
[
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
]
],
[
[
"Trastuzumab emtansine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
],
... | Trastuzumab emtansine may lead to a major life threatening interaction when taken with Prasugrel and Prasugrel may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Trastuzumab emtansine may lead to a major life threatening interaction when taken with Cilostazol and Cilostazol may... |
DB00647 | DB11730 | 675 | 351 | [
"DDInter528",
"DDInter1588"
] | Dextropropoxyphene | Ribociclib | Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the mar... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Major | 2 | [
[
[
675,
25,
351
]
],
[
[
675,
23,
112
],
[
112,
23,
351
]
],
[
[
675,
25,
222
],
[
222,
23,
351
]
],
[
[
675,
24,
283
],
[
283,
62,... | [
[
[
"Dextropropoxyphene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Dextropropoxyphene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Dextropropoxyphene may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Dextropropoxyphene may lead to a major life threatening interaction when taken with Sibutramine and Si... |
DB00494 | DB00835 | 1,533 | 100 | [
"DDInter646",
"DDInter245"
] | Entacapone | Brompheniramine | Entacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease. It is a member of the class of nitrocatechols. When administered concomittantly with levodopa and a decarboxylase inhibitor (e.g., carbidopa), increased and more sustained plasma levodopa conce... | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Moderate | 1 | [
[
[
1533,
24,
100
]
],
[
[
1533,
24,
832
],
[
832,
24,
100
]
],
[
[
1533,
63,
128
],
[
128,
24,
100
]
],
[
[
1533,
24,
649
],
[
649,
... | [
[
[
"Entacapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Entacapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
],... | Entacapone may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Entacapone may cause a moderate interaction that could exacerbate diseases when taken with Dexbromp... |
DB00427 | DB00776 | 1,233 | 1,335 | [
"DDInter1879",
"DDInter1360"
] | Triprolidine | Oxcarbazepine | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exis... | Moderate | 1 | [
[
[
1233,
24,
1335
]
],
[
[
1233,
24,
1264
],
[
1264,
63,
1335
]
],
[
[
1233,
24,
1236
],
[
1236,
1,
1335
]
],
[
[
1233,
63,
902
],
[
902,... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxcarbazepine"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine and Ca... |
DB08826 | DB15091 | 1,292 | 676 | [
"DDInter489",
"DDInter1901"
] | Deferiprone | Upadacitinib | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
1292,
25,
676
]
],
[
[
1292,
24,
1193
],
[
1193,
23,
676
]
],
[
[
1292,
25,
283
],
[
283,
24,
676
]
],
[
[
1292,
64,
248
],
[
248,
... | [
[
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Deferiprone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zinc gluconate"
],
[
"Zi... | Deferiprone may cause a moderate interaction that could exacerbate diseases when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Upadacitinib
Deferiprone may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib ... |
DB00019 | DB06616 | 1,257 | 594 | [
"DDInter1405",
"DDInter224"
] | Pegfilgrastim | Bosutinib | Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, [filgrastim]. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti... | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Moderate | 1 | [
[
[
1257,
24,
594
]
],
[
[
1257,
24,
663
],
[
663,
24,
594
]
],
[
[
1257,
24,
1619
],
[
1619,
63,
594
]
],
[
[
1257,
24,
985
],
[
985,
... | [
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
... | Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib an... |
DB00344 | DB01181 | 1,302 | 1,532 | [
"DDInter1543",
"DDInter906"
] | Protriptyline | Ifosfamide | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may ... | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
1302,
24,
1532
]
],
[
[
1302,
21,
28956
],
[
28956,
60,
1532
]
],
[
[
1302,
63,
1648
],
[
1648,
24,
1532
]
],
[
[
1302,
25,
351
],
[
3... | [
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Protriptyline",
"{u} (Compound) causes {v} (Side Effect)",
"Palpitations"
],
[
"Palpitations",
"{u} (Side Eff... | Protriptyline (Compound) causes Palpitations (Side Effect) and Palpitations (Side Effect) is caused by Ifosfamide (Compound)
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when take... |
DB00814 | DB05773 | 1,171 | 1,047 | [
"DDInter1143",
"DDInter1848"
] | Meloxicam | Trastuzumab emtansine | Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is ... | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Moderate | 1 | [
[
[
1171,
24,
1047
]
],
[
[
1171,
24,
848
],
[
848,
24,
1047
]
],
[
[
1171,
1,
1027
],
[
1027,
24,
1047
]
],
[
[
1171,
24,
1613
],
[
1613,... | [
[
[
"Meloxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Meloxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
... | Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Meloxicam (Compound) resembles Piroxicam (Compound) and Piroxicam may cause a moderate interaction that ... |
DB00945 | DB08896 | 1,479 | 292 | [
"DDInter20",
"DDInter1576"
] | Acetylsalicylic acid | Regorafenib | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Major | 2 | [
[
[
1479,
25,
292
]
],
[
[
1479,
6,
6017
],
[
6017,
45,
292
]
],
[
[
1479,
21,
29276
],
[
29276,
60,
292
]
],
[
[
1479,
24,
643
],
[
643,
... | [
[
[
"Acetylsalicylic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Regorafenib"
]
],
[
[
"Acetylsalicylic acid",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compo... | Acetylsalicylic acid (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Regorafenib (Compound)
Acetylsalicylic acid (Compound) causes Haemoglobin (Side Effect) and Haemoglobin (Side Effect) is caused by Regorafenib (Compound)
Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases... |
DB11817 | DB12498 | 1,259 | 76 | [
"DDInter165",
"DDInter1238"
] | Baricitinib | Mogamulizumab | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become canc... | Major | 2 | [
[
[
1259,
25,
76
]
],
[
[
1259,
62,
1461
],
[
1461,
23,
76
]
],
[
[
1259,
64,
1531
],
[
1531,
24,
76
]
],
[
[
1259,
63,
496
],
[
496,
... | [
[
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mogamulizumab"
]
],
[
[
"Baricitinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin ... | Baricitinib may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Mogamulizumab
Baricitinib may lead to a major life threatening interaction when taken with Canakinumab and Canakinumab may cause... |
DB01156 | DB11130 | 593 | 407 | [
"DDInter252",
"DDInter1344"
] | Bupropion | Opium | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Major | 2 | [
[
[
593,
25,
407
]
],
[
[
593,
63,
409
],
[
409,
24,
407
]
],
[
[
593,
64,
529
],
[
529,
24,
407
]
],
[
[
593,
24,
418
],
[
418,
63,... | [
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Opium"
]
],
[
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Felodipine"
],
[
"Felodipine",
... | Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Felodipine and Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Bupropion may lead to a major life threatening interaction when taken with Fluvoxamine and Fluvoxamine may cause a mod... |
DB06589 | DB06603 | 1,250 | 39 | [
"DDInter1400",
"DDInter1387"
] | Pazopanib | Panobinostat | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
1250,
25,
39
]
],
[
[
1250,
62,
1247
],
[
1247,
23,
39
]
],
[
[
1250,
63,
912
],
[
912,
24,
39
]
],
[
[
1250,
24,
221
],
[
221,
... | [
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Pazopanib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfam... | Pazopanib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Interferon be... |
DB08870 | DB09498 | 850 | 810 | [
"DDInter228",
"DDInter1715"
] | Brentuximab vedotin | Strontium chloride Sr-89 | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer. Bone metastases is a common and severe complication presented in advanced stag... | Moderate | 1 | [
[
[
850,
24,
810
]
],
[
[
850,
63,
552
],
[
552,
24,
810
]
],
[
[
850,
24,
1060
],
[
1060,
63,
810
]
],
[
[
850,
24,
350
],
[
350,
2... | [
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when ... |
DB00284 | DB06343 | 1,647 | 1,379 | [
"DDInter11",
"DDInter1766"
] | Acarbose | Teprotumumab | Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are r... | Teprotumumab is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor. Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 2016 and was approved by th... | Moderate | 1 | [
[
[
1647,
24,
1379
]
],
[
[
1647,
23,
1645
],
[
1645,
24,
1379
]
],
[
[
1647,
24,
1021
],
[
1021,
24,
1379
]
],
[
[
1647,
23,
135
],
[
135... | [
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teprotumumab"
]
],
[
[
"Acarbose",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metformin"
],
[
"... | Acarbose may cause a minor interaction that can limit clinical effects when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Teprotumumab
Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide and Pramlintide... |
DB00252 | DB00491 | 362 | 127 | [
"DDInter1460",
"DDInter1217"
] | Phenytoin | Miglitol | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the bod... | Moderate | 1 | [
[
[
362,
24,
127
]
],
[
[
362,
21,
28792
],
[
28792,
60,
127
]
],
[
[
362,
24,
1194
],
[
1194,
62,
127
]
],
[
[
362,
24,
1486
],
[
1486,
... | [
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miglitol"
]
],
[
[
"Phenytoin",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal disorder"
],
[
"Gastrointestinal disorder",
... | Phenytoin (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Miglitol (Compound)
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Ranitidine and Ranitidine may cause a minor interaction that can limit clinical effec... |
DB00619 | DB14730 | 1,419 | 1,412 | [
"DDInter909",
"DDInter264"
] | Imatinib | Calaspargase pegol | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) . Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparagina... | Moderate | 1 | [
[
[
1419,
24,
1412
]
],
[
[
1419,
24,
792
],
[
792,
24,
1412
]
],
[
[
1419,
63,
883
],
[
883,
24,
1412
]
],
[
[
1419,
25,
484
],
[
484,
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
],
... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and G... |
DB00445 | DB01083 | 322 | 1,142 | [
"DDInter655",
"DDInter1348"
] | Epirubicin | Orlistat | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | The global prevalence of obesity is increasing rapidly. Obesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare. In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological or surgical inter... | Moderate | 1 | [
[
[
322,
24,
1142
]
],
[
[
322,
6,
5599
],
[
5599,
45,
1142
]
],
[
[
322,
7,
8606
],
[
8606,
46,
1142
]
],
[
[
322,
6,
3641
],
[
3641,
... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orlistat"
]
],
[
[
"Epirubicin",
"{u} (Compound) binds {v} (Gene)",
"PLA2G4A"
],
[
"PLA2G4A",
"{u} (Gene) is bound by {v} (Compound)",... | Epirubicin (Compound) binds PLA2G4A (Gene) and PLA2G4A (Gene) is bound by Orlistat (Compound)
Epirubicin (Compound) upregulates ALDOC (Gene) and ALDOC (Gene) is upregulated by Orlistat (Compound)
Epirubicin (Compound) binds DHCR7 (Gene) and DHCR7 (Gene) is upregulated by Orlistat (Compound)
Epirubicin (Compound) downre... |
DB01105 | DB12887 | 222 | 1,598 | [
"DDInter1665",
"DDInter1750"
] | Sibutramine | Tazemetostat | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA approval on 23 January 2020. | Moderate | 1 | [
[
[
222,
24,
1598
]
],
[
[
222,
25,
1039
],
[
1039,
24,
1598
]
],
[
[
222,
62,
752
],
[
752,
24,
1598
]
],
[
[
222,
63,
1324
],
[
1324,
... | [
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
]
],
[
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
],
[
"D... | Sibutramine may lead to a major life threatening interaction when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Sibutramine may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidin... |
DB01165 | DB14568 | 1,539 | 982 | [
"DDInter1325",
"DDInter1000"
] | Ofloxacin | Ivosidenib | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Major | 2 | [
[
[
1539,
25,
982
]
],
[
[
1539,
62,
112
],
[
112,
23,
982
]
],
[
[
1539,
63,
543
],
[
543,
24,
982
]
],
[
[
1539,
24,
28
],
[
28,
2... | [
[
[
"Ofloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Ofloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazo... | Ofloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Lopera... |
DB00705 | DB01105 | 441 | 222 | [
"DDInter496",
"DDInter1665"
] | Delavirdine | Sibutramine | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Minor | 0 | [
[
[
441,
23,
222
]
],
[
[
441,
6,
8374
],
[
8374,
45,
222
]
],
[
[
441,
21,
29215
],
[
29215,
60,
222
]
],
[
[
441,
24,
384
],
[
384,
... | [
[
[
"Delavirdine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
]
],
[
[
"Delavirdine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Delavirdine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sibutramine (Compound)
Delavirdine (Compound) causes Ecchymosis (Side Effect) and Ecchymosis (Side Effect) is caused by Sibutramine (Compound)
Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib a... |
DB00986 | DB11130 | 1,192 | 407 | [
"DDInter834",
"DDInter1344"
] | Glycopyrronium | Opium | Glycopyrronium, also known as NVA237 or glycopyrrolate, is a racemic mixture of two enantiomers. They are both quaternary ammonium compounds and long acting muscarinic antagonists. It is one of the most commonly prescribed anticholinergic medications.[A233535,A233540] Early research into glycopyrronium use was for its ... | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
1192,
24,
407
]
],
[
[
1192,
63,
662
],
[
662,
24,
407
]
],
[
[
1192,
24,
1241
],
[
1241,
24,
407
]
],
[
[
1192,
62,
685
],
[
685,
... | [
[
[
"Glycopyrronium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Glycopyrronium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
... | Glycopyrronium may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Glycopyrronium may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazol... |
DB00001 | DB00939 | 1,578 | 1,338 | [
"DDInter1037",
"DDInter1135"
] | Lepirudin | Meclofenamic acid | Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches. Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence o... | A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. | Moderate | 1 | [
[
[
1578,
24,
1338
]
],
[
[
1578,
24,
1479
],
[
1479,
63,
1338
]
],
[
[
1578,
25,
1347
],
[
1347,
24,
1338
]
],
[
[
1578,
25,
1564
],
[
15... | [
[
[
"Lepirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Lepirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
... | Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid
Lepirudin may lead to a major life threatening interaction when taken with Clopidogrel... |
DB05015 | DB06589 | 1,077 | 1,250 | [
"DDInter174",
"DDInter1400"
] | Belinostat | Pazopanib | Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with... | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
1077,
24,
1250
]
],
[
[
1077,
63,
440
],
[
440,
24,
1250
]
],
[
[
1077,
24,
1270
],
[
1270,
63,
1250
]
],
[
[
1077,
24,
1683
],
[
1683... | [
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Filgrastim"
],
[
... | Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Filgrastim and Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified pr... |
DB00015 | DB00881 | 582 | 954 | [
"DDInter1585",
"DDInter1554"
] | Reteplase | Quinapril | Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids p... | Quinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat.[L8420,L8423] It is used to treat hypertension and heart failure.[L8420,L8423] ACE inhibitors are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta b... | Moderate | 1 | [
[
[
582,
24,
954
]
],
[
[
582,
24,
1638
],
[
1638,
1,
954
]
],
[
[
582,
25,
365
],
[
365,
63,
954
]
],
[
[
582,
24,
885
],
[
885,
63... | [
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trandolapril"
],
[
... | Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril (Compound) resembles Quinapril (Compound)
Reteplase may lead to a major life threatening interaction when taken with Dalteparin and Dalteparin may cause a moderate interaction that could exacerbate di... |
DB01611 | DB06414 | 1,487 | 655 | [
"DDInter893",
"DDInter703"
] | Hydroxychloroquine | Etravirine | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 10... | Moderate | 1 | [
[
[
1487,
24,
655
]
],
[
[
1487,
25,
786
],
[
786,
40,
655
]
],
[
[
1487,
21,
28723
],
[
28723,
60,
655
]
],
[
[
1487,
63,
168
],
[
168,
... | [
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rilpivirine"
],
[
... | Hydroxychloroquine may lead to a major life threatening interaction when taken with Rilpivirine and Rilpivirine (Compound) resembles Etravirine (Compound)
Hydroxychloroquine (Compound) causes Malnutrition (Side Effect) and Malnutrition (Side Effect) is caused by Etravirine (Compound)
Hydroxychloroquine may cause a mode... |
DB01394 | DB12010 | 1,554 | 214 | [
"DDInter431",
"DDInter785"
] | Colchicine | Fostamatinib | Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as _Colchicum autumnale_, or "autumn crocus." Its use was first approved by the FDA in 1961. Colchicine is used in the treatment of gout flares and Familial Mediterranean fever, and prevention of major cardiovascular events. It has ... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
1554,
24,
214
]
],
[
[
1554,
64,
723
],
[
723,
24,
214
]
],
[
[
1554,
63,
973
],
[
973,
24,
214
]
],
[
[
1554,
24,
310
],
[
310,
... | [
[
[
"Colchicine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Colchicine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aprepitant"
],
[
"Aprepita... | Colchicine may lead to a major life threatening interaction when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Colchicine may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may caus... |
DB00023 | DB00317 | 305 | 883 | [
"DDInter127",
"DDInter810"
] | Asparaginase Escherichia coli | Gefitinib | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. | Moderate | 1 | [
[
[
305,
24,
883
]
],
[
[
305,
24,
594
],
[
594,
40,
883
]
],
[
[
305,
24,
1195
],
[
1195,
1,
883
]
],
[
[
305,
24,
984
],
[
984,
63... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib (Compound) resembles Gefitinib (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Erlotinib and Erlotinib (Compound)... |
DB01229 | DB01611 | 973 | 1,487 | [
"DDInter1378",
"DDInter893"
] | Paclitaxel (protein-bound) | Hydroxychloroquine | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Moderate | 1 | [
[
[
973,
24,
1487
]
],
[
[
973,
21,
28658
],
[
28658,
60,
1487
]
],
[
[
973,
63,
723
],
[
723,
24,
1487
]
],
[
[
973,
24,
1623
],
[
1623,
... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Paclitaxel",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) i... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine
Paclitaxel (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Hydroxychloroquine (Compound)
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB01124 | DB09389 | 1,411 | 517 | [
"DDInter1828",
"DDInter1315"
] | Tolbutamide | Norgestrel | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer ([levonorgestrel]) is biologically active. | Moderate | 1 | [
[
[
1411,
24,
517
]
],
[
[
1411,
24,
52
],
[
52,
24,
517
]
],
[
[
1411,
64,
86
],
[
86,
24,
517
]
],
[
[
1411,
63,
1645
],
[
1645,
2... | [
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
],
[... | Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide and Dulaglutide may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Tolbutamide may lead to a major life threatening interaction when taken with Miconazole and Miconazole may ca... |
DB00812 | DB09074 | 998 | 1,362 | [
"DDInter1451",
"DDInter1327"
] | Phenylbutazone | Olaparib | A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit conside... | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
998,
24,
1362
]
],
[
[
998,
40,
576
],
[
576,
24,
1362
]
],
[
[
998,
24,
1683
],
[
1683,
24,
1362
]
],
[
[
998,
63,
79
],
[
79,
... | [
[
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Phenylbutazone",
"{u} (Compound) resembles {v} (Compound)",
"Methadone"
],
[
"Methadone",
"{u} may cause a mod... | Phenylbutazone (Compound) resembles Methadone (Compound) and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that... |
DB01125 | DB11703 | 279 | 405 | [
"DDInter98",
"DDInter9"
] | Anisindione | Acalabrutinib | Anisindione is a synthetic anticoagulant and an indanedione derivative. Its anticoagulant action is mediated through the inhibition of the vitamin K-mediated gamma-carboxylation of precursor proteins that are critical in forming the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagu... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Major | 2 | [
[
[
279,
25,
405
]
],
[
[
279,
24,
557
],
[
557,
24,
405
]
],
[
[
279,
23,
918
],
[
918,
24,
405
]
],
[
[
279,
63,
353
],
[
353,
24,... | [
[
[
"Anisindione",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Anisindione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deoxycholic acid"
],
[
... | Anisindione may cause a moderate interaction that could exacerbate diseases when taken with Deoxycholic acid and Deoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Anisindione may cause a minor interaction that can limit clinical effects when taken with Bicalu... |
DB00280 | DB00675 | 494 | 888 | [
"DDInter575",
"DDInter1744"
] | Disopyramide | Tamoxifen | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Major | 2 | [
[
[
494,
25,
888
]
],
[
[
494,
1,
11392
],
[
11392,
40,
888
]
],
[
[
494,
1,
675
],
[
675,
25,
888
]
],
[
[
494,
35,
832
],
[
832,
4... | [
[
[
"Disopyramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tamoxifen"
]
],
[
[
"Disopyramide",
"{u} (Compound) resembles {v} (Compound)",
"Methadyl Acetate"
],
[
"Methadyl Acetate",
"{u} (Compound) resemble... | Disopyramide (Compound) resembles Methadyl Acetate (Compound) and Methadyl Acetate (Compound) resembles Tamoxifen (Compound)
Disopyramide (Compound) resembles Dextropropoxyphene (Compound) and Dextropropoxyphene may lead to a major life threatening interaction when taken with Tamoxifen
Disopyramide (Compound) resembles... |
DB01255 | DB09472 | 633 | 1,383 | [
"DDInter1078",
"DDInter1693"
] | Lisdexamfetamine | Sodium sulfate | Lisdexamfetamine is a prodrug of [dextroamphetamine], a central nervous system stimulant known as d-amphetamine, covalently attached to the naturally occurring amino acid L-lysine. Lisdexamfetamine is the first chemically formulated prodrug stimulant and was first approved by the FDA in April 2008. It was also approved... | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
633,
24,
1383
]
],
[
[
633,
63,
609
],
[
609,
24,
1383
]
],
[
[
633,
24,
1342
],
[
1342,
24,
1383
]
],
[
[
633,
25,
1618
],
[
1618,
... | [
[
[
"Lisdexamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Lisdexamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromy... | Lisdexamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Lisdexamfetamine may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB09481 | DB11703 | 460 | 405 | [
"DDInter1113",
"DDInter9"
] | Magnesium carbonate | Acalabrutinib | Magnesium carbonate, also known as magnesite, is a common over the counter remedy for heartburn and upset stomach caused by overproduction of acid in the stomach [FDA Label]. | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Moderate | 1 | [
[
[
460,
24,
405
]
],
[
[
460,
63,
478
],
[
478,
24,
405
]
],
[
[
460,
62,
1194
],
[
1194,
24,
405
]
],
[
[
460,
63,
463
],
[
463,
2... | [
[
[
"Magnesium carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Magnesium carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niloti... | Magnesium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Magnesium carbonate may cause a minor interaction that can limit clinical effects when taken with Rani... |
DB01128 | DB06717 | 918 | 875 | [
"DDInter204",
"DDInter778"
] | Bicalutamide | Fosaprepitant | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. | Moderate | 1 | [
[
[
918,
24,
875
]
],
[
[
918,
63,
723
],
[
723,
1,
875
]
],
[
[
918,
21,
29122
],
[
29122,
60,
875
]
],
[
[
918,
63,
473
],
[
473,
... | [
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
... | Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant (Compound) resembles Fosaprepitant (Compound)
Bicalutamide (Compound) causes Mediastinal disorder (Side Effect) and Mediastinal disorder (Side Effect) is caused by Fosaprepitant (Compound)
Bicalutamide... |
DB05239 | DB06688 | 866 | 1,430 | [
"DDInter425",
"DDInter1677"
] | Cobimetinib | Sipuleucel-T | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Moderate | 1 | [
[
[
866,
24,
1430
]
],
[
[
866,
63,
869
],
[
869,
24,
1430
]
],
[
[
866,
25,
676
],
[
676,
63,
1430
]
],
[
[
866,
24,
1531
],
[
1531,
... | [
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[... | Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Cobimetinib may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may ... |
DB00197 | DB00370 | 1,324 | 1,251 | [
"DDInter1881",
"DDInter1230"
] | Troglitazone | Mirtazapine | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6... | Moderate | 1 | [
[
[
1324,
24,
1251
]
],
[
[
1324,
24,
392
],
[
392,
63,
1251
]
],
[
[
1324,
24,
1010
],
[
1010,
24,
1251
]
],
[
[
1324,
63,
521
],
[
521,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mirtazapine"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Mirtazapine
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mef... |
DB04908 | DB11979 | 1,671 | 1,320 | [
"DDInter741",
"DDInter625"
] | Flibanserin | Elagolix | Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
1671,
24,
1320
]
],
[
[
1671,
62,
168
],
[
168,
23,
1320
]
],
[
[
1671,
24,
1297
],
[
1297,
24,
1320
]
],
[
[
1671,
25,
129
],
[
129,
... | [
[
[
"Flibanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Flibanserin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
... | Flibanserin may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Elagolix
Flibanserin may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodro... |
DB00697 | DB00704 | 876 | 267 | [
"DDInter1821",
"DDInter1263"
] | Tizanidine | Naltrexone | Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury. It may also be caused by musculoskeletal injury. Regardless of the cause, muscle spasticity can be an extremely painful and debili... | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Moderate | 1 | [
[
[
876,
24,
267
]
],
[
[
876,
64,
475
],
[
475,
25,
267
]
],
[
[
876,
18,
8386
],
[
8386,
57,
267
]
],
[
[
876,
21,
28695
],
[
28695,
... | [
[
[
"Tizanidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
]
],
[
[
"Tizanidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
... | Tizanidine may lead to a major life threatening interaction when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Naltrexone
Tizanidine (Compound) downregulates MTHFD2 (Gene) and MTHFD2 (Gene) is downregulated by Naltrexone (Compound)
Tizanidine (Compound) causes Dyspnoe... |
DB00361 | DB01234 | 134 | 1,220 | [
"DDInter1939",
"DDInter513"
] | Vinorelbine | Dexamethasone | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Moderate | 1 | [
[
[
134,
24,
1220
]
],
[
[
134,
5,
11555
],
[
11555,
44,
1220
]
],
[
[
134,
6,
8374
],
[
8374,
45,
1220
]
],
[
[
134,
7,
8587
],
[
8587,
... | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Vinorelbine",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (D... | Vinorelbine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Dexamethasone (Compound)
Vinorelbine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dexamethasone (Compound)
Vinorelbine (Compound) upregulates RRS1 (Gene) and RRS1 (Gene) is upregulated by Dexamethas... |
DB00738 | DB01001 | 485 | 688 | [
"DDInter1420",
"DDInter1632"
] | Pentamidine | Salbutamol | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Moderate | 1 | [
[
[
485,
24,
688
]
],
[
[
485,
24,
455
],
[
455,
24,
688
]
],
[
[
485,
24,
1148
],
[
1148,
63,
688
]
],
[
[
485,
6,
8374
],
[
8374,
... | [
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
... | Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Is... |
DB06168 | DB10316 | 1,531 | 334 | [
"DDInter281",
"DDInter1248"
] | Canakinumab | Mumps virus strain B level jeryl lynn live antigen | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease. | Major | 2 | [
[
[
1531,
25,
334
]
],
[
[
1531,
63,
1042
],
[
1042,
24,
334
]
],
[
[
1531,
24,
594
],
[
594,
25,
334
]
],
[
[
1531,
64,
1057
],
[
1057,
... | [
[
[
"Canakinumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"... | Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Mumps virus strain B level jeryl lynn live antigen
Canakinumab may cause a moderate interaction that could exacerb... |
DB00188 | DB10315 | 168 | 1,137 | [
"DDInter222",
"DDInter1127"
] | Bortezomib | Measles virus vaccine live attenuated | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Measles virus vaccine live attenuated is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease. The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture. | Major | 2 | [
[
[
168,
25,
1137
]
],
[
[
168,
64,
581
],
[
581,
25,
1137
]
],
[
[
168,
24,
384
],
[
384,
25,
1137
]
],
[
[
168,
23,
1101
],
[
1101,
... | [
[
[
"Bortezomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Bortezomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
... | Bortezomib may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisi... |
DB01124 | DB09154 | 1,411 | 1,475 | [
"DDInter1828",
"DDInter1686"
] | Tolbutamide | Sodium citrate | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Sodium citrate is the sodium salt of citric acid. It is white, crystalline powder or white, granular crystals, slightly deliquescent in moist air, freely soluble in water, practically insoluble in alcohol. Like citric acid, it has a sour taste. From the medical point of view, it is used as alkalinizing agent. It works ... | Minor | 0 | [
[
[
1411,
23,
1475
]
],
[
[
1411,
24,
1603
],
[
1603,
23,
1475
]
],
[
[
1411,
62,
556
],
[
556,
23,
1475
]
],
[
[
1411,
63,
610
],
[
610,
... | [
[
[
"Tolbutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium citrate"
]
],
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Captopril"
],
[... | Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Captopril and Captopril may cause a minor interaction that can limit clinical effects when taken with Sodium citrate
Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Valproic acid and Val... |
DB08881 | DB11113 | 868 | 657 | [
"DDInter1925",
"DDInter307"
] | Vemurafenib | Castor oil | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic... | Moderate | 1 | [
[
[
868,
24,
657
]
],
[
[
868,
64,
1079
],
[
1079,
24,
657
]
],
[
[
868,
25,
927
],
[
927,
63,
657
]
],
[
[
868,
25,
985
],
[
985,
2... | [
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Vemurafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Telavancin"
],
[
"Telavanc... | Vemurafenib may lead to a major life threatening interaction when taken with Telavancin and Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Vemurafenib may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate ... |
DB01059 | DB01181 | 956 | 1,532 | [
"DDInter1313",
"DDInter906"
] | Norfloxacin | Ifosfamide | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Minor | 0 | [
[
[
956,
23,
1532
]
],
[
[
956,
6,
8717
],
[
8717,
45,
1532
]
],
[
[
956,
21,
28956
],
[
28956,
60,
1532
]
],
[
[
956,
40,
1299
],
[
1299,... | [
[
[
"Norfloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ifosfamide"
]
],
[
[
"Norfloxacin",
"{u} (Compound) binds {v} (Gene)",
"CYP2A6"
],
[
"CYP2A6",
"{u} (Gene) is bound by {v} (Compound)",... | Norfloxacin (Compound) binds CYP2A6 (Gene) and CYP2A6 (Gene) is bound by Ifosfamide (Compound)
Norfloxacin (Compound) causes Palpitations (Side Effect) and Palpitations (Side Effect) is caused by Ifosfamide (Compound)
Norfloxacin (Compound) resembles Trovafloxacin (Compound) and Trovafloxacin may cause a minor interact... |
DB00740 | DB11837 | 424 | 1,297 | [
"DDInter1596",
"DDInter1351"
] | Riluzole | Osilodrostat | A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis. Riluzole is marketed as Rilutek by Sanofi. | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Moderate | 1 | [
[
[
424,
24,
1297
]
],
[
[
424,
63,
322
],
[
322,
24,
1297
]
],
[
[
424,
62,
1684
],
[
1684,
24,
1297
]
],
[
[
424,
24,
1619
],
[
1619,
... | [
[
[
"Riluzole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Riluzole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
... | Riluzole may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Riluzole may cause a minor interaction that can limit clinical effects when taken with Caffeine and Caffeine may... |
DB00069 | DB00900 | 367 | 45 | [
"DDInter946",
"DDInter544"
] | Interferon alfacon-1 | Didanosine | Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional am... | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-termi... | Moderate | 1 | [
[
[
367,
24,
45
]
],
[
[
367,
24,
36
],
[
36,
63,
45
]
],
[
[
367,
25,
1292
],
[
1292,
63,
45
]
],
[
[
367,
63,
491
],
[
491,
24,
... | [
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Didanosine"
]
],
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribuli... | Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Didanosine
Interferon alfacon-1 may lead to a major life threatening interaction when taken with Deferiprone and Defe... |
DB01129 | DB01263 | 379 | 859 | [
"DDInter1559",
"DDInter1494"
] | Rabeprazole | Posaconazole | Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion. | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Moderate | 1 | [
[
[
379,
24,
859
]
],
[
[
379,
6,
8374
],
[
8374,
45,
859
]
],
[
[
379,
21,
30178
],
[
30178,
60,
859
]
],
[
[
379,
24,
913
],
[
913,
... | [
[
[
"Rabeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
]
],
[
[
"Rabeprazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Rabeprazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Posaconazole (Compound)
Rabeprazole (Compound) causes Neck stiffness (Side Effect) and Neck stiffness (Side Effect) is caused by Posaconazole (Compound)
Rabeprazole may cause a moderate interaction that could exacerbate diseases when taken with Ap... |
DB00278 | DB09030 | 291 | 840 | [
"DDInter117",
"DDInter1945"
] | Argatroban | Vorapaxar | Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant sh... | Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expr... | Major | 2 | [
[
[
291,
25,
840
]
],
[
[
291,
23,
944
],
[
944,
62,
840
]
],
[
[
291,
24,
765
],
[
765,
24,
840
]
],
[
[
291,
63,
529
],
[
529,
24,... | [
[
[
"Argatroban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vorapaxar"
]
],
[
[
"Argatroban",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",
... | Argatroban may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Vorapaxar
Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Hemin and Hemin may cause a ... |
DB00959 | DB01261 | 1,486 | 170 | [
"DDInter1191",
"DDInter1679"
] | Methylprednisolone | Sitagliptin | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Moderate | 1 | [
[
[
1486,
24,
170
]
],
[
[
1486,
6,
8374
],
[
8374,
45,
170
]
],
[
[
1486,
21,
28921
],
[
28921,
60,
170
]
],
[
[
1486,
24,
52
],
[
52,
... | [
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Methylprednisolone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by... | Methylprednisolone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sitagliptin (Compound)
Methylprednisolone (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Sitagliptin (Compound)
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when take... |
DB00424 | DB00844 | 19 | 314 | [
"DDInter896",
"DDInter1257"
] | Hyoscyamine | Nalbuphine | Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine]. It is commonly extracted from plants in the _Solanaceae_ or nightshade family. Research into the action of hyoscyamine in published literature dates back to 1826. Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimus... | A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States. | Moderate | 1 | [
[
[
19,
24,
314
]
],
[
[
19,
24,
828
],
[
828,
40,
314
]
],
[
[
19,
63,
421
],
[
421,
1,
314
]
],
[
[
19,
63,
475
],
[
475,
25,
... | [
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nalbuphine"
]
],
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
],
[
... | Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone and Oxycodone (Compound) resembles Nalbuphine (Compound)
Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone (Compound) resembles Nalbuphine (Comp... |
DB09121 | DB11988 | 1,328 | 270 | [
"DDInter140",
"DDInter1321"
] | Aurothioglucose | Ocrelizumab | Aurothioglucose, also known as gold thioglucose, was formerly used to treat rheumatoid arthritis. Contemporary research on the effect of gold salts treatment began in 1935, primarily to reduce inflammation and to slow disease progression in patients with rheumatoid arthritis. The use of gold compounds has decreased sin... | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-human... | Moderate | 1 | [
[
[
1328,
24,
270
]
],
[
[
1328,
63,
134
],
[
134,
24,
270
]
],
[
[
1328,
64,
1520
],
[
1520,
24,
270
]
],
[
[
1328,
24,
1480
],
[
1480,
... | [
[
[
"Aurothioglucose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Aurothioglucose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
... | Aurothioglucose may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Aurothioglucose may lead to a major life threatening interaction when taken with Primaquine and Primaqui... |
DB01110 | DB12941 | 86 | 466 | [
"DDInter1209",
"DDInter481"
] | Miconazole | Darolutamide | Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-ba... | Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate canc... | Minor | 0 | [
[
[
86,
23,
466
]
],
[
[
86,
63,
1622
],
[
1622,
23,
466
]
],
[
[
86,
24,
1623
],
[
1623,
23,
466
]
],
[
[
86,
62,
1091
],
[
1091,
2... | [
[
[
"Miconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voriconazole"
],
[
... | Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole and Voriconazole may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Isavuconazonium a... |
DB00515 | DB00903 | 589 | 1,680 | [
"DDInter387",
"DDInter686"
] | Cisplatin | Etacrynic acid | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as ... | Moderate | 1 | [
[
[
589,
24,
1680
]
],
[
[
589,
21,
28989
],
[
28989,
60,
1680
]
],
[
[
589,
24,
1042
],
[
1042,
63,
1680
]
],
[
[
589,
25,
497
],
[
497,
... | [
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etacrynic acid"
]
],
[
[
"Cisplatin",
"{u} (Compound) causes {v} (Side Effect)",
"Hyperuricaemia"
],
[
"Hyperuricaemia",
"{u} (Side Eff... | Cisplatin (Compound) causes Hyperuricaemia (Side Effect) and Hyperuricaemia (Side Effect) is caused by Etacrynic acid (Compound)
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases whe... |
DB00582 | DB08912 | 1,622 | 1,040 | [
"DDInter1946",
"DDInter462"
] | Voriconazole | Dabrafenib | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increase... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
1622,
24,
1040
]
],
[
[
1622,
6,
8374
],
[
8374,
45,
1040
]
],
[
[
1622,
21,
28900
],
[
28900,
60,
1040
]
],
[
[
1622,
63,
168
],
[
16... | [
[
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Voriconazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Voriconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dabrafenib (Compound)
Voriconazole (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Dabrafenib (Compound)
Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Bor... |
DB00364 | DB00685 | 417 | 1,299 | [
"DDInter1717",
"DDInter1887"
] | Sucralfate | Trovafloxacin | Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia. It is considered a _cytoprotective agent_, protect... | Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective again... | Moderate | 1 | [
[
[
417,
24,
1299
]
],
[
[
417,
24,
872
],
[
872,
40,
1299
]
],
[
[
417,
21,
28845
],
[
28845,
60,
1299
]
],
[
[
417,
24,
286
],
[
286,
... | [
[
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trovafloxacin"
]
],
[
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gemifloxacin"
],
... | Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Trovafloxacin (Compound)
Sucralfate (Compound) causes Oedema (Side Effect) and Oedema (Side Effect) is caused by Trovafloxacin (Compound)
Sucralfate may cause a moderate interact... |
DB00046 | DB01324 | 1,179 | 178 | [
"DDInter940",
"DDInter1490"
] | Insulin lispro | Polythiazide | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826) | Moderate | 1 | [
[
[
1179,
24,
178
]
],
[
[
1179,
24,
674
],
[
674,
40,
178
]
],
[
[
1179,
24,
964
],
[
964,
23,
178
]
],
[
[
1179,
24,
52
],
[
52,
6... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polythiazide"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trichlormethiazid... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide and Trichlormethiazide (Compound) resembles Polythiazide (Compound)
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Doxycycline and Doxycycline may cause a min... |
DB00468 | DB00477 | 1,424 | 216 | [
"DDInter1557",
"DDInter363"
] | Quinine | Chlorpromazine | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | Moderate | 1 | [
[
[
1424,
24,
216
]
],
[
[
1424,
24,
1178
],
[
1178,
1,
216
]
],
[
[
1424,
25,
684
],
[
684,
40,
216
]
],
[
[
1424,
24,
1237
],
[
1237,
... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpromazine"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
],
[... | Quinine may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Chlorpromazine (Compound)
Quinine may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine (Compound) resembles Chlorpromazine (Compound)... |
DB00261 | DB06699 | 702 | 774 | [
"DDInter93",
"DDInter493"
] | Anagrelide | Degarelix | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH... | Major | 2 | [
[
[
702,
25,
774
]
],
[
[
702,
64,
521
],
[
521,
1,
774
]
],
[
[
702,
21,
29232
],
[
29232,
60,
774
]
],
[
[
702,
23,
112
],
[
112,
... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Degarelix"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} (Com... | Anagrelide may lead to a major life threatening interaction when taken with Goserelin and Goserelin (Compound) resembles Degarelix (Compound)
Anagrelide (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Degarelix (Compound)
Anagrelide may cause a minor interaction that can limit clinica... |
DB01105 | DB04946 | 222 | 924 | [
"DDInter1665",
"DDInter907"
] | Sibutramine | Iloperidone | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Moderate | 1 | [
[
[
222,
24,
924
]
],
[
[
222,
63,
1664
],
[
1664,
1,
924
]
],
[
[
222,
24,
519
],
[
519,
40,
924
]
],
[
[
222,
6,
8374
],
[
8374,
4... | [
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloperidone"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
... | Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Iloperidone (Compound)
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone and Paliperidone (Compound) resembles Iloperidone (... |
DB00470 | DB00652 | 530 | 234 | [
"DDInter601",
"DDInter1421"
] | Dronabinol | Pentazocine | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97) | Moderate | 1 | [
[
[
530,
24,
234
]
],
[
[
530,
24,
1359
],
[
1359,
40,
234
]
],
[
[
530,
21,
28762
],
[
28762,
60,
234
]
],
[
[
530,
24,
537
],
[
537,
... | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentazocine"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dezocine"
],
[
... | Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Dezocine and Dezocine (Compound) resembles Pentazocine (Compound)
Dronabinol (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Pentazocine (Compound)
Dronabinol may cause a moderate interaction that... |
DB00530 | DB04865 | 1,195 | 4 | [
"DDInter667",
"DDInter1335"
] | Erlotinib | Omacetaxine mepesuccinate | Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR)... | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Moderate | 1 | [
[
[
1195,
24,
4
]
],
[
[
1195,
7,
14560
],
[
14560,
46,
4
]
],
[
[
1195,
18,
4811
],
[
4811,
46,
4
]
],
[
[
1195,
6,
9842
],
[
9842,
... | [
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Erlotinib",
"{u} (Compound) upregulates {v} (Gene)",
"STAP2"
],
[
"STAP2",
"{u} (Gene) is upregula... | Erlotinib (Compound) upregulates STAP2 (Gene) and STAP2 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Erlotinib (Compound) downregulates DUSP6 (Gene) and DUSP6 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Erlotinib (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is upregulated by Omace... |
DB00307 | DB09074 | 1,101 | 1,362 | [
"DDInter202",
"DDInter1327"
] | Bexarotene | Olaparib | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
1101,
24,
1362
]
],
[
[
1101,
24,
627
],
[
627,
63,
1362
]
],
[
[
1101,
24,
896
],
[
896,
24,
1362
]
],
[
[
1101,
25,
139
],
[
139,
... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bictegravir"
],
[
... | Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Bictegravir and Bictegravir may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposi... |
DB01138 | DB11730 | 804 | 351 | [
"DDInter1726",
"DDInter1588"
] | Sulfinpyrazone | Ribociclib | A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Moderate | 1 | [
[
[
804,
24,
351
]
],
[
[
804,
24,
466
],
[
466,
62,
351
]
],
[
[
804,
63,
222
],
[
222,
23,
351
]
],
[
[
804,
24,
310
],
[
310,
24,... | [
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
]... | Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine... |
DB00222 | DB01583 | 245 | 624 | [
"DDInter825",
"DDInter1075"
] | Glimepiride | Liotrix | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Liotrix is a synthetically derived thyroid hormone replacement preparation. It consists of levothyroxine sodium (thyroxine, T4) and liothyronine sodium (triiodothyronine, T3) in a 4 to 1 ratio by weight. Liotrix was developed when it was believed that serum levels of both T4 and T3 were maintained by direct thyroidal s... | Moderate | 1 | [
[
[
245,
24,
624
]
],
[
[
245,
24,
1152
],
[
1152,
1,
624
]
],
[
[
245,
24,
542
],
[
542,
40,
624
]
],
[
[
245,
21,
28936
],
[
28936,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liotrix"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liothyronine"
],
[
... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine (Compound) resembles Liotrix (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine and Levothyroxine (Compound) resembles Liotrix (Comp... |
DB00773 | DB08912 | 896 | 1,040 | [
"DDInter702",
"DDInter462"
] | Etoposide | Dabrafenib | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
896,
24,
1040
]
],
[
[
896,
6,
4973
],
[
4973,
45,
1040
]
],
[
[
896,
7,
2969
],
[
2969,
46,
1040
]
],
[
[
896,
18,
20044
],
[
20044,
... | [
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Etoposide",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Etoposide (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dabrafenib (Compound)
Etoposide (Compound) upregulates CDKN1A (Gene) and CDKN1A (Gene) is upregulated by Dabrafenib (Compound)
Etoposide (Compound) downregulates METRN (Gene) and METRN (Gene) is upregulated by Dabrafenib (Compound)
Etoposide (Compound... |
DB00352 | DB12001 | 482 | 564 | [
"DDInter1814",
"DDInter7"
] | Tioguanine | Abemaciclib | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the trea... | Moderate | 1 | [
[
[
482,
24,
564
]
],
[
[
482,
24,
868
],
[
868,
24,
564
]
],
[
[
482,
63,
58
],
[
58,
24,
564
]
],
[
[
482,
24,
242
],
[
242,
63,
... | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
... | Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alef... |
DB00502 | DB01166 | 1,300 | 477 | [
"DDInter853",
"DDInter379"
] | Haloperidol | Cilostazol | Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the do... | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Major | 2 | [
[
[
1300,
25,
477
]
],
[
[
1300,
6,
8374
],
[
8374,
45,
477
]
],
[
[
1300,
21,
28892
],
[
28892,
60,
477
]
],
[
[
1300,
23,
112
],
[
112,
... | [
[
[
"Haloperidol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cilostazol"
]
],
[
[
"Haloperidol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Cilos... | Haloperidol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cilostazol (Compound)
Haloperidol (Compound) causes Cardiac arrest (Side Effect) and Cardiac arrest (Side Effect) is caused by Cilostazol (Compound)
Haloperidol may cause a minor interaction that can limit clinical effects when taken with Metronid... |
DB09065 | DB09128 | 760 | 1,241 | [
"DDInter424",
"DDInter231"
] | Cobicistat | Brexpiprazole | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM). It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. Although it is structurally similar to [aripiprazole], brexpiprazole has different b... | Major | 2 | [
[
[
760,
25,
1241
]
],
[
[
760,
63,
761
],
[
761,
24,
1241
]
],
[
[
760,
64,
129
],
[
129,
24,
1241
]
],
[
[
760,
25,
913
],
[
913,
... | [
[
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brexpiprazole"
]
],
[
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
],
[
"Saxagl... | Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole
Cobicistat may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide m... |
DB01064 | DB01227 | 1,148 | 1,301 | [
"DDInter987",
"DDInter1043"
] | Isoprenaline | Levacetylmethadol | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Levacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well... | Major | 2 | [
[
[
1148,
25,
1301
]
],
[
[
1148,
64,
494
],
[
494,
1,
1301
]
],
[
[
1148,
63,
307
],
[
307,
1,
1301
]
],
[
[
1148,
24,
144
],
[
144,
... | [
[
[
"Isoprenaline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levacetylmethadol"
]
],
[
[
"Isoprenaline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Disopyramide"
],
[
"Disopyramide... | Isoprenaline may lead to a major life threatening interaction when taken with Disopyramide and Disopyramide (Compound) resembles Levacetylmethadol (Compound)
Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil (Compound) resembles Levacetylmethadol (Compo... |
DB00046 | DB00647 | 1,179 | 675 | [
"DDInter940",
"DDInter528"
] | Insulin lispro | Dextropropoxyphene | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the mar... | Moderate | 1 | [
[
[
1179,
24,
675
]
],
[
[
1179,
24,
494
],
[
494,
1,
675
]
],
[
[
1179,
24,
954
],
[
954,
40,
675
]
],
[
[
1179,
24,
820
],
[
820,
... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextropropoxyphene"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Disopyramid... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide and Disopyramide (Compound) resembles Dextropropoxyphene (Compound)
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril (Compound) resembles Dext... |
DB00019 | DB00081 | 1,257 | 273 | [
"DDInter1405",
"DDInter1838"
] | Pegfilgrastim | Tositumomab | Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, [filgrastim]. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti... | Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine). | Moderate | 1 | [
[
[
1257,
24,
273
]
],
[
[
1257,
24,
869
],
[
869,
63,
273
]
],
[
[
1257,
25,
1064
],
[
1064,
64,
273
]
],
[
[
1257,
24,
1213
],
[
1213,
... | [
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tositumomab"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
... | Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Tositumomab
Pegfilgrastim may lead to a major life threatening interaction when taken with Cladribine and Cladribine may l... |
DB00688 | DB11817 | 955 | 1,259 | [
"DDInter1251",
"DDInter165"
] | Mycophenolate mofetil | Baricitinib | Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This drug is an immunosuppressant combined with drugs such as [Cyclosporine] and corticosteroids to prevent organ rejection after hepatic, ren... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
955,
25,
1259
]
],
[
[
955,
23,
1193
],
[
1193,
23,
1259
]
],
[
[
955,
24,
1430
],
[
1430,
24,
1259
]
],
[
[
955,
25,
1011
],
[
1011,
... | [
[
[
"Mycophenolate mofetil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Mycophenolate mofetil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
]... | Mycophenolate mofetil may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Baricitinib
Mycophenolate mofetil may cause a moderate interaction that could exacerbate diseases when taken... |
DB04948 | DB08895 | 1,084 | 976 | [
"DDInter1083",
"DDInter1825"
] | Lofexidine | Tofacitinib | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hyp... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Moderate | 1 | [
[
[
1084,
24,
976
]
],
[
[
1084,
25,
982
],
[
982,
63,
976
]
],
[
[
1084,
40,
1020
],
[
1020,
24,
976
]
],
[
[
1084,
24,
407
],
[
407,
... | [
[
[
"Lofexidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Lofexidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosideni... | Lofexidine may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Lofexidine (Compound) resembles Clonidine (Compound) and Clonidine may cause a moderate interaction that could exacerbate dise... |
DB00759 | DB00948 | 1,620 | 1,681 | [
"DDInter1783",
"DDInter1207"
] | Tetracycline | Mezlocillin | Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some e... | Semisynthetic ampicillin-derived acylureido penicillin. It has been proposed for infections with certain anaerobes and may be useful in inner ear, bile, and CNS infections. | Moderate | 1 | [
[
[
1620,
24,
1681
]
],
[
[
1620,
63,
916
],
[
916,
1,
1681
]
],
[
[
1620,
24,
514
],
[
514,
1,
1681
]
],
[
[
1620,
1,
1669
],
[
1669,
... | [
[
[
"Tetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mezlocillin"
]
],
[
[
"Tetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicloxacillin"
],
... | Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Dicloxacillin and Dicloxacillin (Compound) resembles Mezlocillin (Compound)
Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Benzylpenicillin and Benzylpenicillin (Compound) resembles... |
DB00461 | DB00945 | 598 | 1,479 | [
"DDInter1254",
"DDInter20"
] | Nabumetone | Acetylsalicylic acid | Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a de... | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | Moderate | 1 | [
[
[
598,
24,
1479
]
],
[
[
598,
6,
10522
],
[
10522,
45,
1479
]
],
[
[
598,
10,
11666
],
[
11666,
49,
1479
]
],
[
[
598,
54,
19122
],
[
19... | [
[
[
"Nabumetone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
]
],
[
[
"Nabumetone",
"{u} (Compound) binds {v} (Gene)",
"PTGS1"
],
[
"PTGS1",
"{u} (Gene) is bound by {v} (Com... | Nabumetone (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Acetylsalicylic acid (Compound)
Nabumetone (Compound) palliates osteoarthritis (Disease) and osteoarthritis (Disease) is palliated by Acetylsalicylic acid (Compound)
Nabumetone (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharm... |
DB00938 | DB05294 | 455 | 1,069 | [
"DDInter1635",
"DDInter1917"
] | Salmeterol | Vandetanib | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Moderate | 1 | [
[
[
455,
24,
1069
]
],
[
[
455,
6,
8374
],
[
8374,
45,
1069
]
],
[
[
455,
21,
28719
],
[
28719,
60,
1069
]
],
[
[
455,
24,
659
],
[
659,
... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vandetanib"
]
],
[
[
"Salmeterol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Salmeterol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vandetanib (Compound)
Salmeterol (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Vandetanib (Compound)
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may... |
DB05773 | DB08886 | 1,047 | 637 | [
"DDInter1848",
"DDInter126"
] | Trastuzumab emtansine | Asparaginase Erwinia chrysanthemi | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-aspar... | Moderate | 1 | [
[
[
1047,
24,
637
]
],
[
[
1047,
63,
491
],
[
491,
24,
637
]
],
[
[
1047,
64,
1479
],
[
1479,
24,
637
]
],
[
[
1047,
25,
936
],
[
936,
... | [
[
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken ... | Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Trastuzumab emtansine may lead to a major life threateni... |
DB00842 | DB11967 | 686 | 710 | [
"DDInter1359",
"DDInter210"
] | Oxazepam | Binimetinib | Oxazepam is an intermediate-acting, 3-hydroxybenzodiazepine used in the treatment of alcohol withdrawal and anxiety disorders. Oxazepam, like related 3-hydroxybenzodiazepine [lorazepam], is considered less susceptible to pharmacokinetic variability based on patient-specific factors (e.g. age, liver disease) - this feat... | Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array... | Moderate | 1 | [
[
[
686,
24,
710
]
],
[
[
686,
1,
905
],
[
905,
24,
710
]
],
[
[
686,
24,
770
],
[
770,
25,
710
]
],
[
[
686,
1,
905
],
[
905,
40,
... | [
[
[
"Oxazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Oxazepam",
"{u} (Compound) resembles {v} (Compound)",
"Lorazepam"
],
[
"Lorazepam",
"{u} may cause a moderate int... | Oxazepam (Compound) resembles Lorazepam (Compound) and Lorazepam may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Oxazepam may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may lead to a major life threatening interacti... |
DB00480 | DB14711 | 1,668 | 779 | [
"DDInter1035",
"DDInter1680"
] | Lenalidomide | Smallpox (Vaccinia) Vaccine, Live | Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of [thalidomide] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenali... | The New York City Board of Health strain of _Vaccinia_ is a viral strain used as a component of some smallpox vaccinations. ACAM2000, a percutaneously administered smallpox vaccine that was approved by the FDA in 2007, contains live antigens of this strain. | Major | 2 | [
[
[
1668,
25,
779
]
],
[
[
1668,
64,
1064
],
[
1064,
25,
779
]
],
[
[
1668,
24,
478
],
[
478,
25,
779
]
],
[
[
1668,
25,
1377
],
[
1377,
... | [
[
[
"Lenalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Lenalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
... | Lenalidomide may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib ... |
DB00375 | DB00959 | 1,037 | 1,486 | [
"DDInter433",
"DDInter1191"
] | Colestipol | Methylprednisolone | Bile acid sequestrants like colestipol have been in use since the 1970s.[FDA Label, F4555, F4567, L6262] And even though such an agent may very well be useful in reducing elevated cholesterol levels and decreasing the risk for atherosclerotic vascular disease due to hypercholesterolemia, colestipol is still generally o... | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Moderate | 1 | [
[
[
1037,
24,
1486
]
],
[
[
1037,
24,
175
],
[
175,
40,
1486
]
],
[
[
1037,
24,
167
],
[
167,
1,
1486
]
],
[
[
1037,
21,
28714
],
[
28714,... | [
[
[
"Colestipol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Colestipol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
... | Colestipol may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Methylprednisolone (Compound)
Colestipol may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles ... |
DB05381 | DB11160 | 172 | 337 | [
"DDInter863",
"DDInter1459"
] | Histamine | Phenyltoloxamine | A depressor amine derived by enzymatic decarboxylation of histidine. It is a powerful stimulant of gastric secretion, a constrictor of bronchial smooth muscle, a vasodilator, and also a centrally acting neurotransmitter. | Phenyltoloxamine is an antihistamine drug with sedative and analgesic effects. It is a H1 receptor blocker and a member of the ethanolamine class of antihistaminergic drugs. It is available in combination products that also contain other analgesics and antitussives such as acetaminophen. Phenyltoloxamine citrate is the... | Moderate | 1 | [
[
[
172,
24,
337
]
],
[
[
172,
63,
820
],
[
820,
24,
337
]
],
[
[
172,
24,
849
],
[
849,
24,
337
]
],
[
[
172,
63,
820
],
[
820,
23,... | [
[
[
"Histamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyltoloxamine"
]
],
[
[
"Histamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
... | Histamine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Phenyltoloxamine
Histamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and ... |
DB00322 | DB09074 | 141 | 1,362 | [
"DDInter742",
"DDInter1327"
] | Floxuridine | Olaparib | An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been... | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
141,
24,
1362
]
],
[
[
141,
24,
896
],
[
896,
24,
1362
]
],
[
[
141,
35,
139
],
[
139,
24,
1362
]
],
[
[
141,
63,
552
],
[
552,
... | [
[
[
"Floxuridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Floxuridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
],
[
... | Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Floxuridine (Compound) resembles Zidovudine (Compound) and Floxuridine may cause a moderate interaction that could ... |
DB00970 | DB14409 | 0 | 1,129 | [
"DDInter466",
"DDInter867"
] | Dactinomycin | Human adenovirus e serotype 4 strain cl-68578 antigen | A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also d... | Human adenovirus e serotype 4 strain cl-68578 antigen is a vaccine. | Moderate | 1 | [
[
[
0,
24,
1129
]
],
[
[
0,
64,
1057
],
[
1057,
24,
1129
]
],
[
[
0,
24,
1683
],
[
1683,
24,
1129
]
],
[
[
0,
63,
134
],
[
134,
24,
... | [
[
[
"Dactinomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Dactinomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
... | Dactinomycin may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Dactinomycin may cause a moderate interaction that could exacerbate diseases when ... |
DB00099 | DB15044 | 440 | 631 | [
"DDInter735",
"DDInter1738"
] | Filgrastim | Tafasitamab | Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the seq... | Tafasitamab is a humanized, CD19-directed cytolytic monoclonal antibody intended for the treatment of B-cell malignancies. It is produced using recombinant DNA technology in Chinese hamster ovary cells, and contains an IgG1/2 hybrid Fc-domain which has been modified with 2 amino acid substitutions to enhance its cytoto... | Moderate | 1 | [
[
[
440,
24,
631
]
],
[
[
440,
24,
4
],
[
4,
24,
631
]
],
[
[
440,
63,
599
],
[
599,
24,
631
]
],
[
[
440,
25,
1064
],
[
1064,
25,
... | [
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tafasitamab"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"... | Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Tafasitamab
Filgrastim may cause a moderate interaction that could exacerbate diseases when t... |
DB00424 | DB00697 | 19 | 876 | [
"DDInter896",
"DDInter1821"
] | Hyoscyamine | Tizanidine | Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine]. It is commonly extracted from plants in the _Solanaceae_ or nightshade family. Research into the action of hyoscyamine in published literature dates back to 1826. Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimus... | Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury . It may also be caused by musculoskeletal injury . Regardless of the cause, muscle spasticity can be an extremely painful and debi... | Moderate | 1 | [
[
[
19,
24,
876
]
],
[
[
19,
18,
4930
],
[
4930,
57,
876
]
],
[
[
19,
21,
29054
],
[
29054,
60,
876
]
],
[
[
19,
24,
401
],
[
401,
6... | [
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tizanidine"
]
],
[
[
"Hyoscyamine",
"{u} (Compound) downregulates {v} (Gene)",
"DLD"
],
[
"DLD",
"{u} (Gene) is downregulated by {v} ... | Hyoscyamine (Compound) downregulates DLD (Gene) and DLD (Gene) is downregulated by Tizanidine (Compound)
Hyoscyamine (Compound) causes Speech disorder (Side Effect) and Speech disorder (Side Effect) is caused by Tizanidine (Compound)
Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken... |
DB01024 | DB09481 | 1,096 | 460 | [
"DDInter1252",
"DDInter1113"
] | Mycophenolic acid | Magnesium carbonate | Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a c... | Magnesium carbonate, also known as magnesite, is a common over the counter remedy for heartburn and upset stomach caused by overproduction of acid in the stomach [FDA Label]. | Moderate | 1 | [
[
[
1096,
24,
460
]
],
[
[
1096,
63,
954
],
[
954,
23,
460
]
],
[
[
1096,
63,
1620
],
[
1620,
24,
460
]
],
[
[
1096,
24,
872
],
[
872,
... | [
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quin... | Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Te... |
DB00344 | DB01176 | 1,302 | 537 | [
"DDInter1543",
"DDInter453"
] | Protriptyline | Cyclizine | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may ... | A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935) | Moderate | 1 | [
[
[
1302,
24,
537
]
],
[
[
1302,
24,
1511
],
[
1511,
63,
537
]
],
[
[
1302,
63,
1242
],
[
1242,
24,
537
]
],
[
[
1302,
24,
104
],
[
104,
... | [
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
]
],
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
... | Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and... |
DB00861 | DB05773 | 914 | 1,047 | [
"DDInter551",
"DDInter1848"
] | Diflunisal | Trastuzumab emtansine | Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear ... | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Moderate | 1 | [
[
[
914,
24,
1047
]
],
[
[
914,
24,
848
],
[
848,
24,
1047
]
],
[
[
914,
63,
372
],
[
372,
24,
1047
]
],
[
[
914,
24,
738
],
[
738,
... | [
[
[
"Diflunisal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Diflunisal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]... | Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine ... |
DB00876 | DB09038 | 1,414 | 1,450 | [
"DDInter658",
"DDInter636"
] | Eprosartan | Empagliflozin | Eprosartan is an angiotensin II receptor antagonist used to treat hypertension. It performs 2 actions on the renin angiotensin system. By preventing the binding of angiotensin II to AT1, vascular smooth muscle relaxes and vasodilation occurs. By inhibiting norepinephrine production, blood pressure is further reduced. | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
1414,
24,
1450
]
],
[
[
1414,
63,
1061
],
[
1061,
24,
1450
]
],
[
[
1414,
24,
1486
],
[
1486,
24,
1450
]
],
[
[
1414,
24,
1455
],
[
14... | [
[
[
"Eprosartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Eprosartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
... | Eprosartan may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Eprosartan may cause a moderate interaction that could exacerbate diseases when taken with Methylpredniso... |
DB08899 | DB11691 | 129 | 1,499 | [
"DDInter649",
"DDInter1258"
] | Enzalutamide | Naldemedine | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opi... | Major | 2 | [
[
[
129,
25,
1499
]
],
[
[
129,
63,
307
],
[
307,
23,
1499
]
],
[
[
129,
64,
932
],
[
932,
24,
1499
]
],
[
[
129,
63,
723
],
[
723,
... | [
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naldemedine"
]
],
[
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
],
[
"Modafi... | Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Naldemedine
Enzalutamide may lead to a major life threatening interaction when taken with Mifepristone and Mifepristone may c... |
DB00312 | DB05239 | 1,023 | 866 | [
"DDInter1423",
"DDInter425"
] | Pentobarbital | Cobimetinib | A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Dr... | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Moderate | 1 | [
[
[
1023,
24,
866
]
],
[
[
1023,
24,
214
],
[
214,
63,
866
]
],
[
[
1023,
24,
888
],
[
888,
24,
866
]
],
[
[
1023,
62,
1101
],
[
1101,
... | [
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobimetinib"
]
],
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],... | Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen ... |
DB00372 | DB00450 | 999 | 78 | [
"DDInter1793",
"DDInter603"
] | Thiethylperazine | Droperidol | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as ... | Moderate | 1 | [
[
[
999,
24,
78
]
],
[
[
999,
24,
1300
],
[
1300,
40,
78
]
],
[
[
999,
24,
1568
],
[
1568,
1,
78
]
],
[
[
999,
24,
506
],
[
506,
63,... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Droperidol"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Haloperidol"
... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Haloperidol and Haloperidol (Compound) resembles Droperidol (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Pimozide and Pimozide (Compound) resembles Droperidol (... |
DB00927 | DB08901 | 1,559 | 1,468 | [
"DDInter712",
"DDInter1492"
] | Famotidine | Ponatinib | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Minor | 0 | [
[
[
1559,
23,
1468
]
],
[
[
1559,
24,
478
],
[
478,
24,
1468
]
],
[
[
1559,
18,
1918
],
[
1918,
57,
1468
]
],
[
[
1559,
21,
29271
],
[
292... | [
[
[
"Famotidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ponatinib"
]
],
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
... | Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Famotidine (Compound) downregulates PCNA (Gene) and PCNA (Gene) is downregulated by Ponatinib (Compound)
Famotidine... |
DB00539 | DB01138 | 11 | 804 | [
"DDInter1837",
"DDInter1726"
] | Toremifene | Sulfinpyrazone | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. | Moderate | 1 | [
[
[
11,
24,
804
]
],
[
[
11,
24,
998
],
[
998,
1,
804
]
],
[
[
11,
6,
4973
],
[
4973,
45,
804
]
],
[
[
11,
7,
16703
],
[
16703,
46,
... | [
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfinpyrazone"
]
],
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"
],
... | Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutazone and Phenylbutazone (Compound) resembles Sulfinpyrazone (Compound)
Toremifene (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sulfinpyrazone (Compound)
Toremifene (Compound) upregulates ST3GAL5 (Gene) and... |
DB01005 | DB05273 | 995 | 507 | [
"DDInter894",
"DDInter1638"
] | Hydroxyurea | Samarium (153Sm) lexidronam | Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, h... | Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium ... | Major | 2 | [
[
[
995,
25,
507
]
],
[
[
995,
24,
248
],
[
248,
24,
507
]
],
[
[
995,
63,
563
],
[
563,
24,
507
]
],
[
[
995,
24,
270
],
[
270,
63,... | [
[
[
"Hydroxyurea",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Hydroxyurea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
],
... | Hydroxyurea may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Samarium (153Sm) lexidronam
Hydroxyurea may cause a moderate interaction that could exacerbate diseases when taken... |
DB01075 | DB14881 | 1,376 | 180 | [
"DDInter569",
"DDInter1329"
] | Diphenhydramine | Oliceridine | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Moderate | 1 | [
[
[
1376,
24,
180
]
],
[
[
1376,
63,
401
],
[
401,
24,
180
]
],
[
[
1376,
24,
1637
],
[
1637,
24,
180
]
],
[
[
1376,
74,
100
],
[
100,
... | [
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
... | Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Amyl N... |
DB00367 | DB06206 | 566 | 1,268 | [
"DDInter1061",
"DDInter1719"
] | Levonorgestrel | Sugammadex | Levonorgestrel (LNG) is a synthetic progestogen similar to [Progesterone] used in contraception and hormone therapy.[A181988,T659] Also known as Plan B, it is used as a single agent in emergency contraception, and as a hormonal contraceptive released from an intrauterine device, commonly referred to as an IUD. Some of ... | Sugammadex is a selective relaxant binding agent indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery. Rocuronium bromide and vecuronium bromide are neuromuscular blocking medications that cause temporary paralysis and are especially useful for general ane... | Major | 2 | [
[
[
566,
25,
1268
]
],
[
[
566,
1,
615
],
[
615,
64,
1268
]
],
[
[
566,
40,
1657
],
[
1657,
25,
1268
]
],
[
[
566,
1,
1336
],
[
1336,
... | [
[
[
"Levonorgestrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sugammadex"
]
],
[
[
"Levonorgestrel",
"{u} (Compound) resembles {v} (Compound)",
"Norelgestromin"
],
[
"Norelgestromin",
"{u} may lead to a majo... | Levonorgestrel (Compound) resembles Norelgestromin (Compound) and Norelgestromin may lead to a major life threatening interaction when taken with Sugammadex
Levonorgestrel (Compound) resembles Desogestrel (Compound) and Desogestrel may lead to a major life threatening interaction when taken with Sugammadex
Levonorgestr... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.